A grant to fund the First in Human, Phase 1a clinical study of anti-METH ch-mAb7F9 was awarded to UAMS and InterveXion. This three year, $3 million, award will be used to test the safety of the chimeric antibody in healthy human volunteers.
Recent Posts
- DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse (NIDA)
- InterveXion Names Industry Veteran Keith W. Ward as President and Chief Executive Officer
- InterveXion Announces Expansion of Executive Leadership Team
- Special Report: Pure Meth Imported By Mexican Drug Cartels Threatens Arkansans
- How People with Substance Use Disorders (SUDs) Can Lend a Needed Hand in Addiction Research | Nora’s Blog, NIDA
Archives
- May 2019
- April 2019
- February 2019
- January 2019
- December 2018
- November 2018
- May 2018
- January 2018
- October 2017
- June 2017
- January 2016
- January 2015
- November 2014
- February 2014
- August 2013
- July 2013
- December 2012
- November 2012
- May 2012
- April 2012
- July 2011
- April 2011
- October 2009
- September 2009
- March 2005
- January 2005
Recent Comments